New TB funding trends report finds that funding for TB research in 2020 reached only US$915 million – less than half of investment needed to end TB.

Prioritising AIDS/advanced HIV disease and TB treatment in Unitaid’s Investment Plan and Strategic Framework for 2022-2026.

Trend expected to continue without urgent investments in TB services to recover from impact of COVID-19.

Treatment Action Group (TAG) launches newly available TB chapters of its 2021 Pipeline Report.

Stop TB Partnership highlights devastating and continued impact of COVID-19 pandemic on children affected by TB.

Treatment Action Group releases a patent landscape investigating potential patent barriers for the development and delivery of long-acting formulations for selected hepatitis C and TB medicines.

The TB Europe Coalition releases a new guide for affected community, civil society organizations, National TB Programs and policy makers in Eastern Europe and Central Asia.

The TB Europe Coalition releases a new document, aiming to assist TB civil society organizations and community organizations from EECA countries in influencing national monitoring, data collection and accountability systems.

The World Health Organization issues a new compendium of data and evidence-related tools for use in TB planning and programming.

This new resource provides activists with information about two shorter treatment regimens for drug-sensitive TB, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.